Peter Schulam, professor of urology and chief of Yale’s Department of Urology, will serve as the interim director of Yale Cancer Center and physician-in-chief at Smilow. Lynch joined Yale Cancer Center as director in 2009 and assumed the role of inaugural physician-in-chief at Smilow, which opened that year. During his tenure, more than 130 scientists […]
THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT and the Ontario Institute for Cancer Research announced a call for pre-proposals from Canadian academic investigators focused on early-stage technologies.
TIMOTHY LASH was named leader of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.
KAREN RECKAMP was named medical director for clinical research operations at City of Hope.
FDA granted a Breakthrough Therapy Designation to Lenvima (lenvatinib) in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor-targeted therapy.
THOMAS LYNCH JR., director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven, will leave Yale in August to become chairman and chief executive officer of the Massachusetts General Physicians Organization.
Emma Whitehead was a six-year-old girl battling relapsed leukemia for the third time when her parents were told she had run out of treatments. Her doctors offered one last hope—enrollment in a clinical trial at Children's Hospital of Philadelphia in a completely new immunotherapy. It was a phase I toxicity trial for both children and adult patients, and few patients on phase I trials are ever cured. But Emma's family was given the miracle they had prayed for. Five years later, Emma is now a happy, healthy, 11-year-old girl who likes to play piano and soccer. Emma is cured.
The Dan L. Duncan Cancer Center at Baylor College of Medicine and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai received NCI designations this week.
Here is what Hagop Kantarjian has learned over the past two years of his campaign to lower the prices of cancer drugs:People would rather avoid disputing you head-on.
Many people are studying the rising prices of cancer drugs. A growing group of oncologists want to do something different: they want to give them a downward push.
